HIPERTENSIÓN PULMONAR

Bibliografía de recomendada lectura

HIPERTENSION PULMONAR Dra Pilar Escribano Subías Servicio de Cardiología Unidad Multidisciplinar de HP Hospital Universitario 12 de octubre Madrid BIBLIOGRAFÍA * En negrita los especialmente recomendados 1. Escribano-Subias P, Blanco I, López-Meseguer M, Jimenez Lopez-Guarch C, Roman A, Morales P, Castillo-Palma MJ, Segovia J, Gómez-Sanchez MA, Barberà JA, REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012;40:596-603. 2. Luna-López R, Ruiz Martín A, Escribano Subías P. Pulmonary arterial hypertension. Med Clin (Barc). 2022 Jun 24;158(12):622-629. 3. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev 2017;26(145):170056. 4. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Noordegraaf AV, Delcroix M, Rosenkranz S, ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43:3618-3731. 5. Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, Gorenflo M, Harutyunova S, Lorenz HM, Nagel C, Theobald V, Lichtblau M, Berlier C, Ulrich S, Grünig E, Benjamin N, Distler O. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis 2020;79:370-378.

6. Khanna D, Zhao C, Saggar R, Mathai SC, Chung L, Coghlan JG, Shah M, Hartney J, McLaughlin V. Long-Term Outcomes in Patients With Connective Tissue DiseaseAssociated Pulmonary Arterial Hypertension in the Modern Treatment Era: MetaAnalyses of Randomized, Controlled Trials and Observational Registries. Arthritis Rheumatol 2021;73:837-847. 7. Rubio-Rivas M, Homs NA, Cuartero D, Corbella X. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. Autoimmun Rev 2021;20:102713. 8. Hachulla E, Launay D, Boucly A, Mouthon L, de Groote P, Cottin V, Pugnet G, Prévôt G, Bourlier D, Dauphin C, Chaouat A, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O, Giovannelli J. Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest 2020;157:945-954 9. Brown Z, Proudman S, Morrisroe K, Stevens W, Hansen D, Nikpour M. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. Semin Arthritis Rheum 2021;51:495-512.

10. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, MüllerLadner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR, DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340-9. 11. Young A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, Nagaraja V, McLaughlin V, Khanna D. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis Rheumatol 2021;73:1731-1737. 12. Escribano Subías P, Aurtenetxe Pérez A, Pérez Olivares C, Gómez Climent L, Diago Cabezudo JI, Perelló MF. Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. Expert Rev Respir Med 2021 Apr;15(4):493-504

Hipertensión pulmonar

2

13. Pérez-Olivares C, Segura de la Cal T, Flox-Camacho Á, Nuche J, Tenorio J, Martínez Meñaca A, Cruz-Utrilla A, de la Cruz-Bertolo J, Pérez Núñez M, Consortium SP, Arribas-Ynsaurriaga F, Escribano Subías P. The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. Eur Respir J. 2021 Jun 4;57(6):2100115. 14. Pérez Núñez M, Alonso Charterina S, Pérez-Olivares C, Revilla Ostolaza Y, Morales Ruiz R, Enguita Valls AB, Tenorio JA, Gallego Zazo N, De Pablo Gafas A, Lapunzina P, Rodríguez Chaverri A, Escribano Subías P. Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Veno-Occlusive Disease: Certainties and Uncertainties. Diagnostics (Basel). 2021 Jan 19;11(1):141. doi: 10.3390/diagnostics11010141 15. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ, AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017;76:1219-1227. 16. Kuwana M , Blair C, Takahashi T, Langley J, Coghlan J. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 2020;79:626–634. 17. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon 0, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2017;50:1602493. 18. Pradère P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, ReynaudGaubert M, Claustre J, Le Borgne A, Holm AM, Schultz HH, Knoop C, Godinas L, Fisher AJ, Hirschi S, Gottlieb J, Le Pavec J, Working Group on Heart/Lung Transplantation in Systemic Sclerosis. Lung transplantation for scleroderma lung

Hipertensión pulmonar

3

disease: An international, multicenter, observational cohort study. J Heart Lung Transplant 2018;37:903-911. 19. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB; PULSAR Trial Investigators. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215 20. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023 Jan 6;61(1):2201347. doi: 10.1183/13993003.01347-2022

Hipertensión pulmonar

4